The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report
for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in …

Background The clinical context for using blood eosinophil (EOS) counts as treatment–
response biomarkers in asthma and COPD requires better understanding of EOS …

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients
respond differently to treatment. Blood eosinophils are a potential biomarker to stratify …

Chronic obstructive pulmonary disease (COPD) is a complex condition with pathophysiology
and clinical characteristics that vary in presence and severity between patients (1). This …

The role of the blood eosinophil count as a biomarker predictor of the frequency of
exacerbations and response to corticosteroid treatment in chronic obstructive pulmonary …

Introduction The aim of this study was to examine the association between blood eosinophil
levels and the decline in lung function in individuals aged> 40 years from the general …

In patients with COPD, there is controversy regarding the association of blood eosinophil
(Eos) levels with 1) exacerbation frequency and 2) the effect of inhaled corticosteroids for …

In recent years, heterogeneity in chronic obstructive pulmonary disease (COPD)
inflammatory patterns has been recognized as a basis for more precise treatment …

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive
inflammatory airway disease associated with a significant impact on patients' lives, including …

Background Blood eosinophils have been suggested as a potential biomarker in chronic
obstructive pulmonary disease (COPD), and their stability over time has been investigated in …